Management of Acute CLL Crisis
Understanding "CLL Crisis"
The term "CLL crisis" most commonly refers to Richter's transformation—the transformation of CLL into aggressive diffuse large B-cell lymphoma (DLBCL), which occurs in 2-15% of CLL patients and represents a true oncologic emergency with poor prognosis. 1
True acute lymphoblastic blast crisis in CLL is exceedingly rare and represents monoclonal progression of the disease. 2
Evaluation of Suspected Richter's Transformation
Diagnostic Workup
- Obtain tissue diagnosis via lymph node biopsy or excision—histopathology confirmation is mandatory. 1
- Use PET-CT scan to guide biopsy site selection, targeting areas with highest metabolic activity. 1
- Determine clonal relationship between DLBCL and CLL by comparing IGHV sequences—this is strongly advised as it has major prognostic and therapeutic implications. 1
Prognostic Factors
- Clonally-related DLBCL (same IGHV sequence as original CLL) carries worse prognosis than clonally-unrelated disease. 1
- Prior CLL therapy exposure predicts poorer outcomes. 1
Treatment Approach
For Clonally-Related Richter's Transformation
Initiate DLBCL-directed therapy with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, dexamethasone) as the standard regimen. 1
Critical Treatment Considerations:
- Avoid more intensive regimens like R-hyperCVAD or OFAR—these have not improved outcomes and cause considerable toxicity. 1
- Enroll patients in clinical trials whenever possible, as standard therapies yield short response durations. 1
Consolidation Strategy:
- Proceed to allogeneic stem cell transplantation (alloSCT) in all patients with clonally-related Richter's transformation who have an available donor and sufficient fitness—this is the only potentially curative approach. 1
- Consider autologous SCT only in patients unsuitable for alloSCT. 1
For Clonally-Unrelated Richter's Transformation
Treat as de novo DLBCL using standard DLBCL protocols, as this represents a separate malignancy with better prognosis. 1
Management of Rapid CLL Progression (Non-Richter's)
If the patient has rapid CLL progression without transformation to DLBCL:
For Patients on Targeted Therapy:
- Change therapy immediately if rapid progression occurs on BTK inhibitors or venetoclax. 1
- Stopping continuous BCR inhibitor or venetoclax therapy does not necessarily require immediate alternative treatment if CLL is in remission—monitor closely. 1
For Symptomatic Relapse:
Early relapse (<36 months after fixed-duration therapy or non-response):
- Switch therapeutic regimen to either venetoclax plus rituximab for 24 months OR continuous ibrutinib/acalabrutinib. 1
For TP53 mutation or del(17p) patients with progression:
- Use ibrutinib, acalabrutinib, or venetoclax-based regimens as first-line options. 1
- Consider alloSCT in fit patients with high-risk disease and short remission duration. 1
Supportive Care Considerations
Infection Prevention:
- Universal antimicrobial prophylaxis is not warranted for BTK or BCL-2 inhibitor therapy. 1
- Prevent HBV reactivation in HBsAg-positive patients; for HBsAg-negative/HBcAb-positive patients on combination therapy, follow prophylaxis recommendations for anti-CD20 agents. 1
- Provide immunizations preferably before treatment initiation. 1
Autoimmune Complications:
- Treat autoimmune cytopenias with corticosteroids first-line. 1
- For steroid-refractory cases, consider anti-CD20 antibodies or BCR inhibitors. 1
Key Pitfalls to Avoid
- Do not delay tissue biopsy when Richter's transformation is suspected—clinical deterioration can be rapid. 1
- Do not use intensive chemotherapy regimens beyond R-CHOP for Richter's transformation—toxicity outweighs any potential benefit. 1
- Do not miss the opportunity for alloSCT evaluation in eligible patients with clonally-related Richter's—this is the only chance for long-term disease control. 1
- Do not forget to determine clonal relationship—this fundamentally changes prognosis and treatment approach. 1